FDA clears Wound Management's HemaQuell — 4 highlights

Written by Allison Sobczak | February 19, 2016 | Print  |

Wound Management's Resorbable Orthopedic Products subsidiary received FDA clearance for the HemaQuell Resorbable Bone Wax.

Here are four highlights:


1. HemaQuell is a water soluble material that is used as a tamponade to control bleeding from bone surfaces. It is based on the multi-faceted patent that the company acquired in 2009.


2. HemaQuell will be delivered in a unique patent-pending applicator that allows surgeons to directly apply the waxy product on bleeding bones.


3. The HemaQuell bone hemostasis material is completely resorbed between two and seven days and does not delay healing of bone injury.


4. Wound Management is an emerging commercial stage company with its primary products in the $5 billion worldwide advanced wound care market.


More articles on devices and implants:
Xtant Medical's short interest falls 0.4% — 3 facts
Mazor Robotics earnings surpass estimates — 4 notes
14 things to know about NuVasive

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months